BTK and B-cell chronic lymphocytic leukemia: A first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (Imbruvica) has demonstrated efficacy in clinical trials for relapsed and refractory MCL and CLL (Byrd et al., 2013; Byrd et al., 2014; Wang et al., 2013).